Celsion Corporation (NASDAQ:CLSN) Announces Translational Data From OVATION Study In Latest Diagnosed Advanced Ovarian Cancer Patients
Celsion Corporation (NASDAQ:CLSN) has recently announced the latest translational data from the OVATION study of the Phase 1b dose clinical trials that combined GEN-1, Company’s […]